Jacob Laubach, MD, Oncology, Boston, MA, Brigham and Women's Hospital

JacobP.LaubachMD

Oncology Boston, MA

Hematologic Oncology

Assistant Professor, Harvard Medical School

Dr. Laubach is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Laubach's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology/Oncology, 2005 - 2008
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1999 - 2002
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1999

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2008 - 2021
  • NC State Medical License
    NC State Medical License 2001 - 2009
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins
    Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
    Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoprotein... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Management of Newly Diagnosed Multiple Myeloma Looking Up
    Management of Newly Diagnosed Multiple Myeloma Looking UpJuly 3rd, 2019
  • Mixed Race and 'Matchless': Woman with Rare Cancer Searches for Donor
    Mixed Race and 'Matchless': Woman with Rare Cancer Searches for DonorJune 19th, 2015
  • After Cancer Diagnosis, Hospital CEO Continues to Lead Through COVID-19
    After Cancer Diagnosis, Hospital CEO Continues to Lead Through COVID-19April 30th, 2020

Hospital Affiliations